Health Innovations Pharmacy Recalls Qsymia Capsules Due to Sterility Concerns
Health Innovations Pharmacy is recalling Qsymia capsules due to inspection findings regarding sterility and stability data.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the source text explicitly states that the quality control issues present a risk to sterility and quality assurance, which aligns with the 'Severe' criteria for significant risk reports.
Plain-English summary
Health Innovations Pharmacy, Inc. is recalling Qsymia (Phen 15 mg - Topri 92 mg SR Cap) capsules. The recall is limited to products distributed in North Carolina.
The recall was initiated following recent inspection observations related to quality control procedures. These observations present a risk to the sterility and quality assurance of the medication, as stability data does not support the expiry dates.
Consumers who have purchased this product should contact their healthcare provider for guidance on alternative treatment options.
The recalled product
- Product
- Phen 15 mg - Topri 92 mg SR Cap (Qsymia), Health Innov Pharmacy, 295 Pinehurst Ave, Southern Pines, NC 28387, (910) 246-5155
- Manufacturer
- Health Innovations Pharmacy, Inc
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 65 recalled by Health Innovations Pharmacy, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 65 products in this recall →Related recalls
Same manufacturer · Health Innovations Pharmacy, Inc
See all →- ModerateCarvedilol 1.25 mg/mL Recalled for Sterility and Stability Concerns
FDA (Drugs) · 2015-05-20
- HighProgest Cream Recalled for Sterility and Stability Concerns
FDA (Drugs) · 2015-05-20
- HighHealth Innovations Pharmacy Recalls Phospholine Iodide Eye Drops
FDA (Drugs) · 2015-05-20
- HighNortriptyline Suspension Recalled for Sterility and Stability Concerns
FDA (Drugs) · 2015-05-20
- HighHealth Innovations Pharmacy Recalls Naltrexone Capsules Due to Sterility Concerns
FDA (Drugs) · 2015-05-20
Same hazard · sterility risk
See all →- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereFDA Recalls Rohto Dry-Aid Eye Drops Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighMedline Medical Procedure Kits Recalled for High Endotoxin Levels
FDA (Devices) · 2026-05-06
- HighCook Medical tracheostomy introducer sets labeled with overstated expiration dates
FDA (Devices) · 2026-04-15
Similar recalls
- HighCeftazidime Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-02-01
- SevereNatures Pharmacy Recalls Folic Acid Injections Due to Sterility Concerns
FDA (Drugs) · 2014-03-12
- HighInjectable chlorpheniramine/hyoscyamine recalled for sterility assurance failure
FDA (Drugs) · 2023-02-01
- SevereTrinity Care Solutions Recalls Cefepime Due to Sterility Concerns
FDA (Drugs) · 2014-07-30
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 35 mg/ml Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereGentamycin Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-03-12